Recombinant ulva polysaccharide lyase active aggregate and soluble nanoscale superparticle and application thereof

Through self-assembled recombinant Ulva polysaccharide lyase active aggregates and nanoscale superparticles induced by 24-mer ferritin, the problems of low enzyme yield and insufficient stability of Ulva polysaccharide lyase are solved, and efficient purification and heat are achieved Improved stability and is suitable for the industrial production of Ulva oligosaccharides.

CN118878699APending Publication Date: 2024-11-01THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410862860.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing Ulva polysaccharide lyase has low enzyme yield, insufficient stability and difficulty in isolation and purification. The traditional enzyme immobilization method has the problems of large loss of enzyme activity and high carrier cost.

Method used

Using 24-polymer ferritin-induced self-assembled recombinant Ulva polysaccharide lyase active aggregates, the fusion enzyme is formed by fusing the 24-polymer ferritin gene and the Ulva polysaccharide lyase gene, which is highly efficiently expressed in the host cell and is broken by ultrasonication. Purification of the target protein is achieved to form soluble nanoscale Ulva polysaccharide lyase superparticles.

Benefits of technology

It realizes efficient purification and reusable enzymes, significantly improves the thermal stability of the enzymes, reduces purification costs, and is suitable for industrial production in severe environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878699A_ABST
    Figure CN118878699A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant ulva polysaccharide lyase active aggregate as well as soluble nanoscale superparticles and application thereof. The preparation method comprises the following steps: recombining ulva polysaccharide lyase and 24-polymer ferritin into fusion protein, and enabling the fusion protein to become a micron-sized active aggregate which is easy to precipitate under a specific pH value, so that the recombinant ulva polysaccharide lyase can be subjected to self-precipitation, rapid separation and purification are performed through centrifugation, and further ultrasonic treatment is performed to obtain soluble nano-sized superparticles. The recombinant ulva polysaccharide lyase active aggregate and the nanoscale superparticles thereof are selected as tool enzymes to prepare the ulva oligosaccharide, the dosage of an enzyme preparation is greatly reduced, the efficiency of preparing the ulva oligosaccharide is improved, and the nanoscale ulva polysaccharide lyase superparticles have better thermal stability and can be applied to industrial production of the ulva oligosaccharide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of enzyme engineering, and in particular relates to an active aggregate formed by 24-mer ferritin-induced recombinant ulva polysaccharide lyase, and soluble nano-scale super particles and applications thereof. Background Art

[0002] Ulva polysaccharide lyase is a biological enzyme that can degrade Ulva polysaccharide. Ulva polysaccharide is a polysaccharide substance derived from the cell wall of green algae, which has multiple biological activities and application potentials. The function of Ulva polysaccharide lyase is to break down Ulva polysaccharide into smaller polysaccharide units or oligosaccharides, thereby releasing the nutrients and bioactive substances therein. Ulva polysaccharide lyase has important applications in the fields of food, medicine, biotechnology, etc.

[0003] At present, the main methods for preparing ulva oligosaccharides are acid hydrolysis and enzymatic hydrolysis. Compared with acid hydrolysis, enzymatic hydrolysis has mild conditions, controllable product structure, and is environmentally friendly, so it has attracted widespread attention. Researchers have screened out a variety of ulva polysaccharide degrading enzymes from marine microorganisms, including lysozyme, glycosidase, etc., and applied them to the enzymatic hydrolysis of ulva polysaccharides to prepare oligosaccharides. Xu Fei et al. cloned PL24 ulvan lyase from marine bacteria, which can effectively degrade ulva polysaccharides, and the products are mainly oligosaccharides (FeiXu, et al. Mechanistic Insights into Substrate Recognition and Catalysis of a New Ulvan Lyase of Polysaccharide Lyase Family 24 [J]. Applied and Environmental Microbiology, June 2021, 87: e00412-21.). Although some progress has been made in the enzymatic preparation of Ulva oligosaccharides, it still faces problems such as low enzyme yield, insufficient enzyme stability, and difficulty in separation and purification, and innovative technological breakthroughs are urgently needed.

[0004] In recent years, enzyme immobilization technology has provided new ideas for improving the stability and reusability of enzymes. Immobilizing ulva polysaccharide lyase on a carrier can avoid the inactivation of enzyme molecules and facilitate the recycling of enzymes. Common enzyme immobilization methods include covalent coupling, adsorption, and embedding. Li Na et al. immobilized β-xylosidase on the metal-organic framework UiO-66-NH2. The immobilized R333H / XynF@ZrMOF maintained 50% activity after 5 cycles (Na Li, et al. Co-immobilization of β-xylosidase and endoxylanase on zirconium based metal–organic frameworks for improving xylosidase activity at high temperature and in acetone [J]. Bioresource Technology, 2023, 383: 129240.). Jyoti Kaushal et al. embedded free xylanase (Xy) into a metal organic framework (Cu-BTC MOF), and immobilized (Xy-Cu-BTC) bioconverted xylan (yield 87.4%) to XOS oligoxylose (Jyoti Kaushal, et al. Efficacious bioconversion of waste walnut shells to xylotetrose and xylopentose by free xylanase (Xy) and MOF immobilized xylanase (Xy-Cu-BTC) [J]. Bioresource Technology, 2022, 357: 127-374.). However, the traditional enzyme immobilization method still has the disadvantages of large enzyme activity loss and high carrier cost.

[0005] Therefore, we proposed an integrated strategy of fusing the gene encoding Ulva polysaccharide lyase with 24-mer ferritin to solve the above problems. We utilized the self-assembly property of 24-mer ferritin to construct a spontaneously assembled Ulva polysaccharide lyase-Ferritin fusion enzyme, which was efficiently expressed in host cells and ultrasonically broken, and the target protein could be purified by low-speed centrifugation only. The Ulva polysaccharide lyase active aggregates obtained by this method have good reusability; in addition, the Ulva polysaccharide lyase active aggregates can be dissolved back under specific conditions to form nano-scale Ulva polysaccharide lyase superparticles with better stability. Summary of the invention

[0006] In view of the shortcomings of the prior art, the first purpose of the present invention is to provide a Ferritin-induced self-assembled recombinant Ulva polysaccharide lyase active aggregate and a soluble nano-scale Ulva polysaccharide lyase superparticle. The recombinant Ulva polysaccharide lyase active aggregate has the advantages of being purified under low-speed centrifugation conditions, easy to separate from the product and reusable, and can be applied to the industrial production of specific preparation of Ulva oligosaccharides; the nano-scale Ulva polysaccharide lyase superparticle has an enzyme activity equivalent to that of the wild enzyme, but its thermal stability is greatly improved compared to the wild enzyme, so the superparticle can be used in industrial production in more severe environments.

[0007] In order to achieve the above technical purpose, the inventors combined the research experience of Ulva polysaccharide lyase for many years, and formed a recombinant Ulva polysaccharide lyase active aggregate by fusing the 24-mer ferritin gene. The obtained enzyme active aggregate only needs simple centrifugation to quickly separate the target enzyme from the impurity protein and has enzyme activity. The above-obtained recombinant Ulva polysaccharide lyase active aggregate is subjected to ultrasonic treatment to obtain soluble nano-scale Ulva polysaccharide lyase superparticles. Compared with the inclusion bodies formed by induction, the above two enzymes do not need to be denatured and renatured, and can be used directly, thereby greatly reducing the cost of purifying the enzyme.

[0008] Specifically, the technical solution of the present invention is as follows: a recombinant ulva polysaccharide lyase activity aggregate, comprising ulva polysaccharide lyase and 24-mer ferritin.

[0009] Further preferably, the recombinant Ulva polysaccharide lyase active aggregate further comprises a connecting peptide, and the connecting peptide is located between the Ulva polysaccharide lyase and the 24-mer ferritin.

[0010] Further preferably, the amino acid sequence of the Ulva polysaccharide lyase is shown as SEQ ID NO.1; the amino acid sequence of the 24-mer ferritin is shown as SEQ ID NO.2.

[0011] The invention discloses a soluble nano-scale ulva polysaccharide lyase superparticle, which is obtained by dispersing the above-mentioned recombinant ulva polysaccharide lyase active aggregate in a Tris-HCl buffer solution with a pH of 8.0-9.0 at 4-20 DEG C and then subjecting it to ultrasonic treatment.

[0012] Further preferably, the conditions of the ultrasonic treatment are: ultrasonic power 480-550 W, and ultrasonic time 30-60 min.

[0013] It should be noted that the above-mentioned recombinant Ulva polysaccharide lyase active aggregates have a short rod-like microstructure under a transmission electron microscope, and the particle size is between 500 and 1000 nm; the above-mentioned soluble nano-scale Ulva polysaccharide lyase superparticles have a round granular microstructure under a transmission electron microscope, and the particle size is between 20 and 80 nm.

[0014] The second object of the present invention is to provide a nucleic acid molecule encoding the above-mentioned recombinant Ulva polysaccharide lyase active aggregate, and to provide a recombinant vector comprising the nucleic acid molecule.

[0015] The third object of the present invention is to provide an engineered bacterium, which comprises the above-mentioned recombinant vector. Further preferably, the engineered bacterium is Escherichia coli.

[0016] The fourth object of the present invention is to provide a method for preparing recombinant Ulva polysaccharide lyase active aggregates, which comprises fermenting and culturing the above-mentioned engineered bacteria, ultrasonically disrupting the bacteria, and then centrifuging to obtain recombinant Ulva polysaccharide lyase active aggregates.

[0017] More specifically, a method for preparing a recombinant ulva polysaccharide lyase active aggregate and its nanoscale superparticles comprises the following steps:

[0018] (1) The gene fragment of ulva polysaccharide lyase was introduced into the nucleotide sequence of 24-mer ferritin, and the 24-mer ferritin and ulva polysaccharide lyase gene fragment were combined through a linker (EAAAKEAAAK), and then inserted into the pET-22b(+) plasmid vector to construct the pET-XM47-Ferritin expression vector;

[0019] (2) introducing the pET-XM47-Ferritin plasmid obtained in step (1) into Escherichia coli for expression to produce an engineered bacterium;

[0020] (3) activating the engineered bacteria obtained in step (2) in LB medium, expanding the culture in TB medium, and then adding IPTG to induce expression to obtain a culture solution;

[0021] (4) centrifuging the culture solution obtained in step (3) at 9000-11000 g at room temperature for 10-20 min to obtain a first precipitate and obtain bacterial cells;

[0022] (5) adding the bacterial cells obtained in step (4) to 2-10°C pH 8.0-9.0 Tris-HCl buffer at a volume ratio of bacterial cells to buffer of (20-30):1, oscillating with an oscillator to uniformly suspend the bacterial cells in the buffer and then ultrasonically disrupting them;

[0023] (6) centrifuging the material obtained in step (5) at 3.8-4.2° C. and 4000 g for 10-20 min, discarding the supernatant, adding an appropriate amount of Tris-HCl buffer solution with a pH of 8.0-9.0, and centrifuging again under the same conditions to obtain a second precipitate, that is, obtaining the recombinant Ulva polysaccharide lyase active aggregate;

[0024] (7) Dispersing the recombinant Ulva polysaccharide lyase active aggregates described in step (6) in a pH 8.0-9.0 Tris-HCl buffer and subjecting to ultrasonic treatment to obtain nanoscale Ulva polysaccharide lyase superparticles.

[0025] In a preferred embodiment of the present invention, the nucleotide sequence of the gene fragment of the Ulva polysaccharide lyase is shown as SEQ ID NO.3.

[0026] In a preferred embodiment of the present invention, the nucleotide sequence of the 24-mer ferritin is as shown in SEQ ID NO.4.

[0027] More preferably, the Escherichia coli is E.coil BL21 (DE3).

[0028] Further preferably, the activation in step (3) is to culture to OD 600 =0.5-0.8.

[0029] More preferably, the temperature of the expanded culture in step (3) is 37° C., the culture is carried out on a shaking table at 200 rpm for 3-4 hours, and the inoculation amount is 1:100.

[0030] Further preferably, the conditions of ultrasonic fragmentation in step (5) are: power 300 W, ultrasonication for 2 s each time, interval 4 s, cycle 99 times, and the above is repeated twice.

[0031] Further preferably, the conditions of the ultrasonic treatment in step (7) are: ultrasonic power 480-550W, ultrasonic time 30-60min, ultrasonic temperature 4-25°C. Still further preferably, the conditions of the ultrasonic treatment are: ultrasonic power 510W, ultrasonic time 60min, ultrasonic temperature 20°C.

[0032] The recombinant ulva polysaccharide lyase active aggregates and nano-scale superparticles prepared by the present invention have simple protein expression conditions, convenient purification, and low production cost, and are therefore suitable for industrial production. The present invention provides a new strategy for the separation, purification, and immobilization of recombinant proteins, and has broad application prospects in the fields of biological separation and biomacromolecule immobilization. The recombinant ulva polysaccharide lyase active aggregates can be used as a new type of immobilized enzyme in the industrial production of specific preparation of ulva oligosaccharides, while the nano-scale ulva polysaccharide lyase superparticles are more widely used in industrial production under severe environments.

[0033] Accordingly, the sixth object of the present invention is to provide an application of the above-mentioned recombinant ulva polysaccharide lyase active aggregate and its nanoscale superparticles in the enzymatic preparation of ulva oligosaccharides; and to provide an application of a biomaterial related to the above-mentioned recombinant ulva polysaccharide lyase active aggregate in the enzymatic preparation of ulva oligosaccharides, wherein the biomaterial is any one of the following A1) to A8):

[0034] A1) a nucleic acid molecule encoding the recombinant Ulva polysaccharide lyase activity aggregate;

[0035] A2) an expression cassette containing the nucleic acid molecule described in A1);

[0036] A3) a recombinant vector containing the nucleic acid molecule described in A1);

[0037] A4) a recombinant vector containing the expression cassette described in A2);

[0038] A5) a recombinant microorganism containing the nucleic acid molecule described in A1);

[0039] A6) a recombinant microorganism containing the expression cassette described in A2);

[0040] A7) a recombinant microorganism containing the recombinant vector described in A3);

[0041] A8) A recombinant microorganism containing the recombinant vector described in A4).

[0042] Compared with the prior art, the present invention has the following beneficial effects:

[0043] (1) The present invention recombines Ulva polysaccharide lyase and 24-mer ferritin into a fusion protein, which can be efficiently expressed in the host bacteria, and obtains micron-sized aggregates that are easy to precipitate after ultrasonic disruption of the bacteria, so that the recombinant Ulva polysaccharide lyase can self-precipitate to form active aggregates, which are quickly separated and purified by centrifugation. This purification method is simple to operate, time-saving, has a large processing capacity, and is less restricted by equipment.

[0044] (2) The recombinant ulva polysaccharide lyase active aggregate prepared by the present invention is convenient to store, has stable enzyme activity, has high activity, single product, and can be reused. The ulva polysaccharide lyase active aggregate retains 80% of the initial activity after being recycled for 10 times. In addition, the preparation method has the advantages of simple route and low production cost, and is suitable for industrial production.

[0045] (3) The recombinant Ulva polysaccharide lyase active aggregates prepared by the present invention facilitate the separation of macromolecular proteins (enzymes) from products, reduce the influence of macromolecular proteins on product activity, further purify the enzymatic hydrolysis products, and better retain the active groups of Ulva sugar chains.

[0046] (4) The nano-scale ulva polysaccharide lyase superparticles prepared by the present invention have comparable activity to wild-type ulva polysaccharide lyase. At the same time, the thermal stability of the nano-scale ulva polysaccharide lyase superparticles is significantly improved, and they exhibit excellent heat resistance under more stringent temperature conditions. This new type of bioactive nanomaterial can be applied to the industrial production of ulva oligosaccharides.

[0047] (5) The present invention uses the active aggregates of recombinant Ulva polysaccharide lyase and its nano-scale superparticles as tool enzymes to prepare Ulva oligosaccharides, which greatly reduces the amount of enzyme preparations and improves the efficiency of preparing Ulva oligosaccharides, providing a new idea and method for the industrial production of Ulva oligosaccharides. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 : Map of expression vector plasmid pET-XM47-Ferritin.

[0049] Figure 2 : SDS-PAGE electrophoresis analysis, wherein lane M: marker; lane 1: nano-scale Ulva polysaccharide lyase superparticles; lane 2: Ulva polysaccharide lyase active aggregates; lane 3: wild-type Ulva polysaccharide lyase.

[0050] Figure 3 :Analysis of enzyme activity recovery rate of Ulva polysaccharide lyase active aggregates under different centrifugal forces

[0051] Figure 4: Particle size distribution of the active aggregates of Ulva polysaccharide lyase before and after ultrasonic treatment of the enzyme solution, wherein: a is the particle size distribution before ultrasound, b is the particle size distribution after ultrasound.

[0052] Figure 5: a Transmission electron microscopy morphology of wild-type Ulva polysaccharide lyase; b Transmission electron microscopy morphology of active aggregates of Ulva polysaccharide lyase; c Transmission electron microscopy morphology of nanoscale Ulva polysaccharide lyase superparticles.

[0053] Figure 6 : Analysis of the reuse rate of Ulva polysaccharide lyase active aggregates.

[0054] Figure 7 :The hydrolysis ability of Ulva polysaccharide lyase active aggregates on different substrates

[0055] Figure 8 : HPLC identification of the preparation of Ulva oligosaccharides catalyzed by the active aggregates of Ulva polysaccharide lyase.

[0056] Fig. 9 :FTIR identification of ulva oligosaccharide prepared by catalysis of ulva polysaccharide lyase active aggregates DETAILED DESCRIPTION

[0057] The following examples will further illustrate the present invention in conjunction with the accompanying drawings. If no specific techniques or conditions are specified in the examples, the conventional techniques or conditions described in the literature in the art or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0058] Example 1: Preparation of recombinant Ulva polysaccharide lyase active aggregates

[0059] (1) The gene fragment of ulva polysaccharide lyase was introduced into the nucleotide sequence of 24-mer ferritin, and the 24-mer ferritin and ulva polysaccharide lyase gene fragment were combined through a linker (EAAAKEAAAK), and inserted into the pET-22b(+) plasmid vector to construct the pET-XM47-Ferritin expression vector. Figure 1 The pET-XM47-Ferritin shown in the figure, wherein the amino acid sequence of Ulva polysaccharide lyase is shown in SEQ ID NO.1, the nucleotide sequence of Ulva polysaccharide lyase is shown in SEQ ID NO.3, the amino acid sequence of 24-mer ferritin is shown in SEQ ID NO.2, and the nucleotide sequence of 24-mer ferritin is shown in SEQ ID NO.4.

[0060] SEQ ID NO.1:

[0061] AIKLEHEIKVTDQALFFDGVKKSVPQARTQAYIEGQKYNYAYGNAIAPHGDAIKVYK

[0062] NYVFMTWYRGGILDRHVMLTRYNTLTGKSVTIEFPHQHTGFEGRWWVGETHNTIAV

[0063] AISPKDETIHLLYDMHAYRENTDTGGNGDIRKDYFRYSYSLAGAASVTDNNFTLTQF

[0064] VKDTSVNSEGATDYKHLTMTGIEDHGQFSRLTYPTFFTSHDGDLFLHMRQGSSHDGR

[0065] VVFNKYLAEQGKWSHFKSFNVLGAGKKGEIKNWSIYGKMKYADGKIRIGFQRRFNL

[0066] PDRFRAQDGMFYAYSDDPSGETQWKNYKGEAITMPLVKADEALVMRPGDLLPDAT

[0067] AKDQVSITGGFDWTVTENGDLHLIGQTNEWVNKKVIKKVYSHTYQKAGVGELITTT

[0068] DFPPASQLYTAGENIYIIGLEQGRPFVEQAKGGTNDFTRVYYAPVGSQSFQKGIVHIH

[0069] DGKLYYYLLEKGGAGDKRTTYLQIINLDIDSKSYFKKIKQ

[0070] SEQ ID NO.2:

[0071] TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDDRDDVALKNFAKYFLH

[0072] QSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDCDDWESGLNAMECALHLEKNVNQS

[0073] LLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLF

[0074] DKHTLGDSDNES

[0075] (2) Transforming the pET-XM47-Ferritin obtained in step (1) into Escherichia coli BL21 (DE3) to prepare an engineered bacterium;

[0076] (3) The glycerol bacteria of the engineered bacteria obtained in step (2) were inoculated into LB liquid containing ampicillin (Amp) (100 mg / L) at a volume ratio of 1:100 and cultured for 12 h until the OD 600The value was 0.6, and then the inoculum was inoculated into TB medium at a ratio of 1:100, placed in a shaking incubator at 37°C, cultured at a speed of 200 r / min for 3-4 h, and then IPTG (concentration of 100 mmol / L) was added for induction culture for 24 h to obtain culture fluid;

[0077] (4) The culture solution obtained in step (3) was centrifuged at 10000 g for 20 min at room temperature to obtain a first precipitate, and then Tris-HCl (pH 9.0, 50 mmol) was added at a volume ratio of 20:1 to the culture solution, and the mixture was resuspended and washed three times to obtain bacterial cells;

[0078] (5) Add the bacteria obtained in step (4) to Tris-HCl buffer (pH 9.0, 50 mmol, 2-10° C.) at a volume ratio of 25:1 (bacteria: buffer), and oscillate with an oscillator to uniformly suspend the bacteria in the Tris-HCl buffer for ultrasonic disruption. The conditions for ultrasonic disruption are: power 300 W, 2 s per ultrasonication, 4 s interval, 99 cycles, and the above is repeated twice;

[0079] (6) Centrifuge the material obtained in step (5) containing cell debris at 1500-5500g for 20 min at 4°C. Calculate the enzyme activity recovery rate under different centrifugal forces, and select the centrifugal force with the highest enzyme activity recovery rate for subsequent purification. Enzyme activity recovery rate = (IU - IU 0 ) / IU, where IU is the enzyme activity in cell debris, IU 0 It is the enzyme activity in the supernatant after low-speed centrifugation. After centrifugation, the supernatant is discarded, and under the centrifugal force condition with the highest enzyme activity recovery rate, the same volume of Tris-HCl buffer solution (pH9.0, 50mmol, 2-10℃) is added to the precipitate, blown evenly, and centrifuged for the second time. The precipitate obtained after washing is the recombinant Ulva polysaccharide lyase active aggregate. The obtained material is as follows Figure 2 As shown in lane 2 of Figure 3 As shown, the optimal centrifugal force is 4000g and the enzyme activity recovery rate can reach 77%.

[0080] Example 2: Preparation of Nano-scale Ulva Polysaccharide Lyase Superparticles

[0081] The recombinant Ulva polysaccharide lyase active aggregates prepared in Example 1 were dispersed in Tris-HCl (pH 9.0, 50 mmol) at 20° C., ultrasonically treated at a power of 510 W for 60 min, and centrifuged at 4500 g for 10 min. The supernatant was soluble nanoscale Ulva polysaccharide lyase superparticles.

[0082] Example 3: Morphological analysis of three Ulva polysaccharide lyases

[0083] As shown in Figure 5, the microstructure of the recombinant Ulva polysaccharide lyase active aggregates prepared in Example 1 under a transmission electron microscope is short rod-shaped, and the particle size is between 500 and 1000 nm; the microstructure of the nanoscale Ulva polysaccharide lyase superparticles prepared in Example 2 under a transmission electron microscope is round granular, and the particle size is between 20 and 80 nm; the microstructure of the wild-type Ulva polysaccharide lyase under a transmission electron microscope is round granular, and the particle size is between 90 and 200 nm.

[0084] Example 4: Determination of the Enzyme Activities of Three Ulva Polysaccharide Lyases

[0085] 1.0g of Ulva polysaccharide was added to 50ml of Tris-HCl buffer (pH9.0, 50mmol), and ultrasonically dissolved to prepare a 2% Ulva polysaccharide solution. 100μL of the Ulva polysaccharide lyase active aggregate prepared in Example 1 (0.01g sample dissolved in 100μL Tris-HCl, pH9.0), 100μL of the nano-scale Ulva polysaccharide lyase superparticles prepared in Example 2, and 100μL of the wild-type Ulva polysaccharide lyase were taken, and 1mL of the above Ulva polysaccharide solution was added to each, and the enzymatic reaction was carried out at 25°C for 10min. The activity of the three enzymes was detected, and the results showed that the activity of the Ulva polysaccharide lyase active aggregate was 78.46IU / mL, the activity of the nano-scale Ulva polysaccharide lyase superparticles was 87.03IU / mL, and the activity of the wild-type Ulva polysaccharide lyase was 94.94IU / mL.

[0086] Example 5: Determination of the thermal stability of three ulva polysaccharide lyases

[0087] The active aggregates of Ulva polysaccharide lyase, nano-sized Ulva polysaccharide lyase superparticles and wild-type Ulva polysaccharide lyase were divided into several 2mL EP tubes and incubated in a water bath at 25, 35 and 45℃. Every 1 hour, a tube of enzyme solution was taken out for enzyme activity determination. The half-life was determined by calculating the remaining enzyme activity after different incubation times at different temperatures. The results are as follows:

[0088] Table 1 Half-life of UPL at different temperatures

[0089]

[0090] Note: Free UPLs are wild-type Ulva polysaccharide lyase, mUPLAs are active aggregates of recombinant Ulva polysaccharide lyase, and nUPLSs are nanoscale Ulva polysaccharide lyase superparticles.

[0091] As can be seen from Table 1, at the optimum temperature of 25°C, the half-life of the wild-type enzyme is 14.4h, while that of the nano-sized Ulva polysaccharide lyase superparticles can reach 42.25h. At 45°C, the half-life of the nano-sized Ulva polysaccharide lyase superparticles is 13.27h, which is nearly 8 times higher than that of the wild-type enzyme (1.7h). The nano-sized Ulva polysaccharide lyase exhibits excellent thermal stability.

[0092] Example 6: Aggregates of Ulva polysaccharide lyase activity specifically cleave Ulva polysaccharide

[0093] 2% Ulva polysaccharide, 2% Enteromorpha polysaccharide, 2% Laminaria polysaccharide, and 2% fucoidan solutions were prepared respectively. 1 mL of each polysaccharide solution was added with 0.01 g of the Ulva polysaccharide lyase active aggregate prepared in Example 1. The mixture was reacted at 25°C and pH 9.0 for 1 hour, and the oligosaccharide yield was calculated. Figure 6 It shows that the active aggregate of ulva polysaccharide lyase prepared in Example 1 specifically lyses ulva polysaccharide.

[0094] Example 7: Determination of the reusability of active aggregates of Ulva polysaccharide lyase

[0095] Add 1.0 g of Ulva polysaccharide to 50 ml of Tris-HCl buffer (pH 9.0, 50 mmol), and dissolve it by ultrasonic to prepare a 2% Ulva polysaccharide solution. React the active aggregates of Ulva polysaccharide lyase with the above-mentioned Ulva polysaccharide solution at 25°C for 10 minutes, and measure the enzyme activity. After continuous centrifugation and washing, add new Ulva polysaccharide substrate for the next round of experiments. The enzyme activity of the first round of reaction is 100%, and the relative enzyme activity of each round of reaction is calculated. Repeat 10 rounds in total, and calculate the reuse rate of the active aggregates of Ulva polysaccharide lyase by the enzyme activity. The reuse rate of the active aggregates of Ulva polysaccharide lyase is as follows: Figure 7 As shown, after 10 cycles, the enzyme activity retention rate reached nearly 80%, demonstrating excellent cycling ability.

[0096] Example 8: Molecular weight identification of enzymatic hydrolysis products of Ulva polysaccharide lyase active aggregates

[0097] The molecular weight of the enzymatic hydrolysis product was identified by high performance liquid chromatography. The active aggregate of the ulva polysaccharide lyase prepared in Example 1 was added to the above ulva polysaccharide solution and reacted at 25°C for 12 hours to prepare ulva oligosaccharides. The obtained enzymatic hydrolysis product was dissolved in an aqueous solution to prepare a 2 mg / mL solution, which was filtered through a 0.22 μm aqueous phase filter membrane and analyzed by liquid chromatography. The results are as follows: Figure 8 As shown, the molecular weight of the enzymatic hydrolysis product was calculated to be 492.3D, indicating that the product was mainly disaccharide.

[0098] Example 9: Infrared Identification of Ulva Polysaccharide Lyase Active Aggregates Enzymatic Hydrolysis Products

[0099] In a dry environment, take a sample visible to the naked eye and an appropriate amount of dry potassium bromide powder, add them to a mortar, grind them several times, and put them into a tablet press to form a transparent sheet. When testing, collect the background first, then collect the infrared spectrum of the sample, with a resolution of 4cm-1, 32 scans, and a test wave number range of 400-4000cm-1. The results are as follows Fig. 9 As shown in the figure, the structure of Ulva polysaccharide changed after enzymatic hydrolysis into Ulva oligosaccharide, which was mainly manifested in the movement of the OH stretching vibration peak: reflecting the change of the hydrogen bond network. The more complex and strong hydrogen bond network in the polysaccharide was simplified after enzymatic hydrolysis. The appearance of new characteristic peaks: indicating that new functional groups or chemical bonds may have been formed.

[0100] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of implementation of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.

Claims

1. A recombinant Ulva polysaccharide lyase activity aggregate, comprising Ulva polysaccharide lyase and 24-mer ferritin.

2. The recombinant Ulva polysaccharide lyase active aggregate according to claim 1, characterized in that: It also comprises a connecting peptide, which is located between the Ulva polysaccharide lyase and the 24-mer ferritin; the amino acid sequence of the Ulva polysaccharide lyase is shown as SEQ ID NO.1; the amino acid sequence of the 24-mer ferritin is shown as SEQ ID NO.

2.

3. A soluble nano-scale Ulva polysaccharide lyase superparticle, characterized in that: The method is obtained by dispersing the recombinant ulva polysaccharide lyase active aggregates described in claim 1 or 2 in a Tris-HCl buffer solution with a pH of 8.0-9.0 at 4-20° C. and subjecting the resultant to ultrasonic treatment.

4. The soluble nano-scale Ulva polysaccharide lyase superparticles according to claim 3, characterized in that: The conditions of the ultrasonic treatment are: ultrasonic power 480-550W, and ultrasonic time 30-60min.

5. A nucleic acid molecule encoding the active aggregate of the Ulva polysaccharide lyase according to claim 1. A recombinant vector comprising the nucleic acid molecule according to claim 5 .

7. An engineered bacterium comprising the recombinant vector according to claim 6.

8. A method for preparing active aggregates of recombinant Ulva polysaccharide lyase, the method comprising fermenting and culturing the engineered bacteria according to claim 7, ultrasonically disrupting the bacteria, and then centrifuging to obtain active aggregates of recombinant Ulva polysaccharide lyase.

9. Use of the recombinant ulva polysaccharide lyase active aggregates according to claim 1 or 2, or the soluble nanoscale ulva polysaccharide lyase superparticles according to claim 3 or 4 in the preparation of ulva oligosaccharides by enzymatic hydrolysis of ulva polysaccharides.

10. Use of a biological material related to the active aggregate of the recombinant ulva polysaccharide lyase according to claim 1 or 2 in the preparation of ulva oligosaccharides by enzymatic hydrolysis of ulva polysaccharide, wherein the biological material is any one of the following A1) to A8): A1) a nucleic acid molecule encoding the recombinant Ulva polysaccharide lyase activity aggregate; A2) an expression cassette containing the nucleic acid molecule described in A1); A3) a recombinant vector containing the nucleic acid molecule described in A1); A4) a recombinant vector containing the expression cassette described in A2); A5) a recombinant microorganism containing the nucleic acid molecule described in A1); A6) a recombinant microorganism containing the expression cassette described in A2); A7) a recombinant microorganism containing the recombinant vector described in A3); A8) A recombinant microorganism containing the recombinant vector described in A4).

Citation Information

Patent Citations

  • Nano-enzyme based on human ferritin and preparation method of nano-enzyme

    CN108707618A

  • Method for purifying recombinant xylanase by low-speed centrifugation

    CN112342207A

  • Fusion protein of cytokine and ferritin subunit as well as preparation method and application of fusion protein

    CN117327194A

  • PL24 family ulva polysaccharide lyase, coding gene and mutant and application thereof

    CN117701547A